QTRX
- Quanterix Corporation
()
Overview
Company Summary
Quanterix Corporation (QTRX) is a company that specializes in developing and commercializing ultra-sensitive digital biomarker technology solutions. Their primary focus is on revolutionizing healthcare by enabling precise measurement of biomarkers - molecules that indicate the presence or progression of a disease or condition.
Quanterix's proprietary technology, called Simoa (Single Molecule Array), allows researchers and clinicians to detect and quantify extremely low levels of target molecules in a variety of biological samples, such as blood, saliva, and cerebrospinal fluid. This level of sensitivity provides unprecedented accuracy in the measurement of biomarkers, which can lead to early disease detection, effective therapeutic intervention, and improved patient outcomes.
The applications of Quanterix's technology are vast and span across multiple fields including oncology, neurology, cardiology, infectious diseases, and more. By facilitating the detection of biomarkers with greater precision, Quanterix aims to enable advancements in diagnostics, drug development, and precision medicine.
In addition to their cutting-edge technology, Quanterix also offers a range of instruments, consumables, and services to support their customers in implementing the Simoa platform into their research and diagnostic workflows. They collaborate with various academic institutions, pharmaceutical companies, and clinical laboratories globally.
Overall, Quanterix Corporation focuses on empowering researchers and clinicians with the tools they need to accurately measure and analyze biomarkers, ultimately leading to improved diagnosis, treatment, and monitoring of diseases.